Thirona Spins out the Retina Business to Pursue Long-term Growth Plans

Following the growing market demand and recent expansion of RetCAD™ – Thirona’s flagship AI solution for eye disease screening – Thirona decided to spin out its Retina division into Thirona Retina BV, as per January 1st, 2023.

Thirona specializes in artificial intelligence for lung and retinal image analysis allowing for precise quantification of abnormalities related to pulmonary and eye diseases. The high-precision analyses contribute to development of innovative solutions for screening, diagnostics, and personalized patient treatment.

To advance the company’s ability to anticipate on increasing patients’ needs and to pursue long-term growth plans in both fields of expertise, the company decided to spin out her Retina division.

While building further on the scientific heritage and technology expertise of Thirona in the field of AI-assisted medical image analysis, Thirona Retina BV will focus entirely on the eye diseases market and act as a stand-alone legal entity. Thirona BV will continue to concentrate on AI-powered solutions for precision medicine in lung diseases, in partnership with pharmaceutical, med-tech and clinical care integration companies.

“To ensure business continuity and to allow our new entity to grow in a focused manner, Thirona BV will continue to support the Retina team with shared resources, where needed.”, comments Eva van Rikxoort, Founder and CEO of Thirona. “We are happy to see our Retina business maturing and quickly gaining market traction.”

“We are convinced that this step will allow our Retina team to fully concentrate on the development of AI-powered solutions for eye diseases, to support growing patients’ needs and to intensify partnerships with our channel partners in eye care markets.”, says Mark van Grinsven, Managing Director of Thirona Retina BV. “The Class IIa European MDR CE certified RetCAD™ is already being integrated by all major fundus camera providers such as iCare, Topcon, Canon, Tomey and Nidek. More dedication will allow us to speed up the expansion to other channels and to grow our leadership position globally.”

“This formal separation ensures that both companies are optimally positioned to pursue their growth plans and maximizes the ability to create value in their respective markets .”, says Guido Geerts, Partner and co-CEO of Thirona BV.

SourceThirona

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”